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AQ4N: an alkylam`noanthraquinone N-oxide showing bioreductive
potential and positive interaction with radiation in vivo
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S-y AQ4N(l,4-bLs-q25ddimthyai oo y}amin5dydroxy-anthrane-9,10-dione) is a
novel alkylaminoanthraquinone N-oxide which, on reducin, forms a stable DNA affinic cytotoxi compound
AQ4. The be vivo anti-tumour efficacy of AQ4N was investted in B6D2F, mice bearing the T50/80
mammary inoma. The effect of the drug was evaluated m combinatin with hypobarc hypoxa and with
(single and multiple fraction). Sysemic toxicity was aseed by weight post treatment. This was
low for AQ4N and was less than that obtained with the biorlductive drugs, RSU 1069 (l-[3-azrdinyl-2-
hydroxypropy-2-itroimidale) and SR 4233 (lrApazamine, 3-an1,2,4-beztrzine-1,4-dioxide). The
anti-tumour effect of AQ4N was potentiated in vivo by combination with hypobarc hypoxa with a dose
enhaz~mnent ratio of 5.1. lTis is consistent with the proposal that AQ4N was reduced in vivo to AQ4,
resultng m ehanced anti-tumour toxicity. When AQ4N (200 mgkg-') was combined with single dose
radiaion (12 Gy) the drug was shown to have an additive interaction with radiation This was obtaied even if
the drug was aMinistred from 4 days before to 6 h afte radiation treatment. Equivalent anti-tumour activity
was also shown when both AQ4N (200 mg kg-') and radtion (5 x 3 Gy) were administered in frationated
n In hconclsion, AQ4N shows nt potential as a bioductive drug for combination with
fractionated radiotherapy.
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The failure to cure tumours with radiotherapy and
chemotherapy has been attributed in part to the presence of
treatment-resistant subpopulations of hypoxic tumour cells
(Bush et at., 1978). Bioreductive agents provide a novel
approach to this problem: reduction of the prodrug within a
hypoxic cell to produce a cytotoxic metabolite should selec-
tively target this sub population within tumours. Since nor-
mal tissus contain few, if any, poorly oxygenated cells,
systemic reductive activation and its attendant toxicity should
be minimal.
Several classe of bioreductive agents have been described,
icluding the nitroimidazoles, benzotriazene di-N-oXides and
mitosenes (Workman, 1992). Using a different class of com-
pounds, i.e. the anthraquinones, we have developed a novel
alkylamnoanthraquinone N-oxide, AQ4N (1,4-bis-{[2-(di-
methylamino-N-oxide)ethylarmino}5,8-dihydroxyanthracene-
9,10-ione), which is susceptible to reduction under hypoxic
conditions (Patterson, 1993). AQ4N is a weak DNA-binding
agent and weak topoisomerase H inhibitor, critically, the
electrically neutral N-oxide function prevents stable binding
to the DNA helix (Patterson, 1993). In contrast, the reduc-
tion product ofAQ4N, i.e. AQ4 (1,4-bis-{[2-(dimethylamino)
ethylnamino}5,8-dihydroxyanthracene-9,10-dione) (Figure 1),
is a cationic compound with high affinity for DNA. Interac-
tion ofAQ4 with DNA is facilitated by the planar, eletron-
deficient antraquinone chromophore intercalating between
adjcent DNA bases. Tlis complex is further stabiised by
electrostatic interactions and hydrogen bonding with the
deoxyribose phosphate backbone, as has been observed for
similar anthraquinones (Denny and Wakelin, 1990). The
tiking level of DNA binding of AQ4 is similar in mag-
nitude to that of its suctural analogue, mitoxantrone, a
chemotherapeutic agent which is clnially proven and widely
used in oncology. In addition, like mitoxantrone, AQ4 has
been shown to inhibit topoisomerase II (Patterson, 1993).
Since AQ4N is reduced to a stable DNA affinic cytotoxic
agent it has theoretical potential as a bioreductive drug. The
aim of this present study was to show that AQ4N is active in
vivo. This presents methodological difficulties since an
effective bioreductive drug will trget cells which contribute
only marginall to tumour growth: in many situations
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hypoxic cells are destined to die within a short time period.
There are two main e tal stategies for overcoming
this problem (Workman and Stratford, 1993). Firstly the
tumour may be made more hypoxic (Bremner et al., 1990;
McAleer et al., 1992). This will allow metabolism of the drug
in cells which will contribute, when the hypoxic stimulus is
removed, to the main growth frction within the tumour.
Secondly, the drug can be combined with an agent which is
selectively toxic to well-oxygenated cells to evahuate the effect
of targeting the two subpopulations of cells (Brown and
Lemmon, 1991; Grau and Overgaard, 1991). We have used
both these approaches to study the effect of AQ4N on
tumour growth in vivo. Firstly, we tested the anti-tumour
effect of AQ4N when combined with hypobaric hypoxia.
Following this we combined AQ4N with radiation as both
single and fractionated doses.
Materiak an mth
Tumour system
The T50/80 tumour is a poorly differentiated mammary car-
cinoma which arose in a B6D2FI mouse. Tumour and
breeding colonies for mice were obtained from Dr JV Moore,
Paterson Laboratory, Christie Hospital, Manchster, UK.
Male B6D2FI mice aged 8-12 weeks were used for all
studies, which were carried out in accordance with the UK.
Animals (Scientific Procedures) Act 1986. The tumour has
been maintained by intadermal passage for up to ten pas-
sages and then re-establshed from frozm stock. Tumour brei
(0.05ml) was injected intradermally on the rear dorsum, and
treatment was initiated when the tumour dia reached
6.5-7.5 mm (gometric mean of three orthogonal diameters).
Tumour size was measured three times weekly. The time for
the tumour to reach double its treatment vohlme (tumour
doubling time, TDT) was used as a measure of anti-tumour
effiacy. Tumour growth delay was calculated by subtracing
the mean TDT for control tumours from that obtained in the
test situations.
Drugpreparation, administration andsystemic toxicity
AQ4N was synthsised as previously described (Patterson,
1989) and administered in sterile water. SR 4233 (Tira-S McKeown etn
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Fgu 1 Chemical strt of AQ4N and the reductin product AQ4. The satue of the alkylaminoanthraqumnone N-Oxide
AQN and its four-ekctron rdution product AQ4.
pazamine = 3-amin -1,2,4-benzotiazie-1,4-dioxide) and RSU
1069 (l1-3-aziridinyl-2-hydroxypropylj2-nitroimidazole) were
prepared in phosphate-buffered saline as outlined previously
(McAleer et al., 1992). The drugs were administered by a
single i.p. injection at a range of doses (Table I). The
stemic toxicity of all drugs was using weight loss
2-3 days post treatment, as this was found to be the nadir of
weight loss in almost all mice. Weight loss was plotted
aginst drug dose and rgession lines were fitted.
Dose enhancement ratio determination
For determination of the dose enhancement ratio (DER)
mice were treated with the drug or vehicle and imnmediately
assigned to air-breathing (oxc) or hypobaric (hypoxic) treat-
ment groups. For drug treatment mice were allocated to 3-5
dose levels. The precise drug dose given was calculated for
each mouse and used for the scatter plots. As previously
described (McAleer et al., 1992) mice allocated to hypoxic
treatment were plaed, within 10min of injection, into a
hypobaric chamber at 0.55 atmospheres for 24 h. The effect
of treatment was assessed using TDT. An adjustment was
made for a small increase in TDT observed in vehice-treated
mice exposed to hypoxia as compared with normal atmos-
pheric conditions. This experiment was desgned to evahlate
the putative bioreductive effect of each drug, in terms of the
DER: this can be defined as the ratio of the doses of drug
required to give an equivalent anti-tumour effect under oxic
and hypoxic conditions. The ratio is determined by the
horizontal separation of the palll sn lines of the
scatter plots for oxic and hypoxic groups. For the analysis of
each exeimet two criteria must be fulfilled. Firstly, a
significnt dose-response effect must exist for both oxic and
hypoxic groups. (This was confirmed for each of the drugs
analysed). Secondly, the regession lines of TDT against log
dose for both groups must be parallel. (Analysis of
covariance was used to show that the lines were not
signifiantly non-paralel.) For a more detaile diion of
the mathmatical analysis see Armitage and Berry (1987) and
McAleer et al. (1992). Confidence limits for the DER were
derived using FieLler's theorem (Armitage and Berry, 1987).
Combination ofAQ4N and radation
X-irradiation was min using a 300 kV Simns
Stabilipan (dose rate 2.56 Gymin'1). Unnaesthetised mice
were immobilised in lead jigs with the dorsal tumour exposed
to the radiation beam. Halfway through treatment the jigs
were rotated through 180" to equaw dose distribution to the
tumour. Tumour growth delay was used to assess the efficacy
of treatment.
Single-fraction irradiation was given over a range of doses
from 7.5 to 25 Gy. To study the combination of AQ4N and
radiation, tumour-bearing mnie were treated with a single i.p.
injection of AQ4N (200 mgkg-') at known time intervals
either before or after 12 Gy single fraction irradiation. AQ4N
Tabe 1 The anti-tumour effect of several bioreductve drugs when
tested using hypobaric hypoxia
Dose 95%
Dow range (mgkg-') enhancement confidence
Drug Oxic Hypoxic ratio (DER) mits
AQ4N 20-320 3-130 5.1* 1.8-14.5
SR4233 17-50 3- 24 8.8* 6.5-55
RSU 1069 90-150 14-90 8.5* 7.3-36.3
DER values significantly different from 1.0, P<0.005.
Tumour-bearingmic were treated withdrug andexposed tohypobaric
hypoxia(0.55atmosheres)for24 h(hypoxicgroup). Controlmicewere
kept at normal atmospheric prsure (oxic group). Drugs were
administered over a range ofdoses. The ratio ofdrug doserequired to
give an equivalnt anti-tumour effect was used to determine the dose
hancementratio. UsingFeker'stheorem,95%confidencelmitswere
akulated rIThe DER valus ofSR 4233 and RSU 1069 arereprnted
from McAleer et al. (1992) with kind permission Esevier Science.]
was also administered with an approximately isoeffective
fractionated radiation regimen (5 x 3 Gy) adminisd over
five consecutive days. The drug dose was fixed at
200mgkg-' and adm i 30 min before irradiation.
Three different drug scheduling regimens were used:
200mg kg-' on day 1, lOOmgkg-' on days I and 3 or
40mgkg-' on each of the five consecutive radiation days.
RelAs
Systemic toxicity
Following administration of AQ4N at a range of doses in
oxic and hypoxc mice (Table 1) systemic toxicity was
asses using weight loss following treatment (Figure 2a).
Normally oxygenated mice showed minimal weight loss when
given AQ4N up to doses of 400 mgkg-' (0.9mmolkg-'),
although some mice showed a small weight loss in the range
5-10%. There was no evidence of a dose-response relation-
ship. Systemic toxicity was not increased when administra-
tion of AQ4N at low doses (up to 50mgkg-') was followed
by induction of hypobaric hypoxia (Figure 2a). At higher
doses (100-200mg kg-') there was appreiabl weight loss
(P<0.001), and therefore doses beyond 200mgkg-' were
not tested under hypoxic conditions.
We have also studied the systemic toxcity of the bioreduc-
tive drugs RSU 1069 and SR 4233 under oxic and hypoxic
conditions (Figure 2b and c). When RSU 1069 was given
under oxic conditions there was no signiicnt weight loss
with increasing drug dose up to 150mgkg'. In combination
with hypoxia a signiint increase was found (P<0.001).
For SR 4233 given to normally oxygenated mice there was a
signifiant increase in weight loss up to the normally reported
maximum tolerated dose of 50 mgkg-' (P<0.001). In com-
bination with hypobaric hypoxia there was a signiant
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Fugwe 3 Relationship between tumour growth delay and dose of
drug. The tumour growth delay is plotted against the logarithm
of dose of AQ4N for oxic (0) and hypoxic (U) treatment
groups. The parallel regression lines have been plotted; the dose
enhancement ratio (DER) is the anti-log of the horizontal separa-
tion of the parallel lines.
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Fge 4 Relationship between tumour growth delay and dose of
radiation. Tumour growth delay (mean ± s.e.) plotted against
radiation dose administered as a single fraction.
confidence intervals for all three drugs (Table I) show that
- Qa lJ the DER values are significantly different from 1.0
(P<0.005). This indicates that there is a significant increase
- - -A t.; vc A.
2
X 8 16 32 64
LU LI LY.U.UAIL CLIL;L Ul ac U1 Up-g WIUI Ily - sia, alU is
2rug4dos8 16gkg21) consistent with the proposal that they undergo in vivo
Drug dose (mg kg-l) bioreductive activation.
FJgwe 2 Relationship between percentage weight loss post treat-
ment and dose of bioreductive drug. The weight loss at 2-3 days
post treatment is expressed as a percentage of pretreatment
weight for individual mice. This is plotted against the logarithm
of the drug dose for (a) AQ4N, (b) RSU 1069 and (c) SR 4233.
Mice were treated over a range of drug doses both at normal
atmospheric pressure (oxic, 0) and immediately before induction
of hypobaric hypoxia at 0.55 atmospheres for 24 h (hypoxic, U).
(The data for SR 4233 are reprinted from McAleer et al., 1992.)
enhancement of systemic toxicity in combination with SR
4233, with weight losses of less than 10% only being
observed at very low doses (<6mgkg-').
Tumour response: AQ4N with hypobaric hypoxia
The anti-tumour effect of AQ4N was assessed by comparing
the dose-response curves in mice treated at 1 and 0.55
atmospheres. There was a left shift of the dose-response
curve under hypoxic conditions with a DER of 5.1 (Figure
3). The values derived previously for SR 4233 and RSU 1069
were 8.8 and 8.5 respectively (McAleer et al., 1992). The
DER results obtained for the three drugs were not
significantly different from each other. However, the 95%
Twnour response: AQ4N and single dose radiation
With single fractions of radiation ranging from 7.5 to 25 Gy
there was increasng tumour growth delay (Figure 4). For 12
Gy tumour growth delay was 6.93 (s.e. = 0.95). When AQ4N
(200 mg kg-') was given alone the tumour growth delay was
3.09 (s.e. = 0.50). In combination these modalities (AQ4N,
200 mg kg'; radiation, 12 Gy) gave a tumour growth delay
of approximately 18 days (Figure 5). From the radiation
dose-response curve 24 Gy, as a single dose, is required to
give an 18 day growth delay. Thus AQ4N reduced by 50%
the radiation dose required to give an anti-tumour effect
equivalent to that of radiation alone.
In order to maximise the benefit from drug-radiation
interactions, it was important to identify the most effective
time interval between administration of the two modalities.
Initially the drug was administered at a range of times from
90 min before to 60 min after radiation treatment. All of
these schedules gave an additive effect with tumour growth
delays of approxiimately 18 days (no significant difference).
The scheduling experiment was repeated twice using a wider
range of time to identify the period over which the additive
interaction could be obtained. The interaction was present
over a long time period, with the maximal interaction being
observed when the drug was administered from 4 days before
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FJigre 5 Tumour growth delay when AQ4N was administered
before or after a single dose of radiation (12 Gy). AQ4N
(200mgkg-') was administered at a range of times up to 120h
before and 48 h after a single dose of X-irradiation (12Gy).
Tumour growth delay (mean ± s.e.) (6-18 animals per group) is
plotted against time of administration. Bars show the tumour
growth delay obtained for AQ4N and radiation administered
alone (mean ± s.e.). The results are the pooled data from three
experiments.
to 6 h after the radiation treatment (Figure 5). An app-
reciable, but diminishing, effect was still seen when the drug
was administered up to 48 h after radiation.
Tumour response: AQ4N withfractionated radiation
In clinical practice, radiotherapy is given as a fractionated
regimen. Therefore, AQ4N was assessed for its anti-tumour
efficacy when administered with 15 Gy given in five daily
fractions of 3 Gy (Figure 6). Drug was administered in all
schedules 30 min before irradiation. When given as a single
dose (1 x 200 mg kg-') AQ4N gave a marked enhancement
of anti-tumour effect as compared with either modality alone
(P<0.01). AQ4N given in two doses (2 x 100 mg kg-')
slightly improved the outcome. When AQ4N was given on
each day of radiation treatment, but with the same total dose
(i.e. 5 x 40 mg kg-'), the anti-tumour effect was significntly
increased as compared with the single-dose AQ4N with a
fractionated radiation regimen (P<0.01) (Figure 6). This
combination was as effective as that obtained when single
doses of both modalities were combined.
AQ4N is a novel alkylaminoanthraquinone N-oxide which
shows minimal cytotoxicity to cells even at high concentra-
tions (Patterson et al., 1995). On exposure to a hypoxic
cellular environment the major metabolite formed is AQ4;
this is a stable, cytotoxic compound with high affinity for
DNA. The hypoxic cytotoxicity of AQ4N to V79 cells is
twice that found under normal oxygenation. This can be
increased to 100 times when rat liver microsomes are present,
suggesting that reductive metabolism of AQ4N requires the
presence of specific microsomal enzymes (Patterson, 1993). It
is known that metabolism of AQ4N involves cytochrome
P450 (Graham et al., 1993), which is normally down-
regulated in vitro (Krupski et al., 1985). This could explain
why only limited reduction of AQ4N is found in vitro. We
have recently shown that excised T50/80 tumour cells can
metabolise AQ4N under hypoxic conditions but that this
ability is lost in isolated cells within 24 h (unpublished data).
Several advantages result from the differences in the
chemical properties ofAQ4N and its reduction product AQ4.
Firstly, the stability of AQ4 and its high binding affinity for
DNA allows for a long residence time in the cells in which it
is formed. The demonstrated long interval of interaction
between drug and radiation (Figure 5) suggests that this can
occur in vivo. It is also consistent with the evidence that
Fige 6 Tumour growth delay when AQ4N was administered
in combination with fractionated radiation (5 x 3 Gy). AQ4N
(200 mg kg-') was administered 30 min before radiation. The
drug was given as a single dose on the first day of treatment, or
in multiple doses as indicated. A single dose of drug
(200 mg kg-') combined with fractionated radiation was
significantly different from fractionated radiation alone
(P<0.01). Multiple doses of drug (5 x 40mg kg-') with frac-
tionated radiation was significantly more effective than a single
dose of drug when combined with fractionated radiation
(P<0.01). The results of single-dose radiation (12 Gy) in com-
bination with AQ4N (200 mg kg-') are included for comparison.
mitoxantrone, a close analogue of AQ4, has a long elimina-
tion half-life in vivo of several hours to days (reviewed by
Faulds et al., 1991). In contrast, the elimination half-life of
AQ4N in mice following i.p. administration is approximately
30 min (LH Patterson and MA Graham, unpublished
results); this is consistent with the low affinity of AQ4N for
DNA. Secondly, when AQ4 is bound to DNA, it acts as a
topoisomerase II inhibitor (Patterson, 1993; PJ Smith, per-
sonal communication). Thus, AQ4 should be cytotoxic to the
cell in which it is formed, even if that cell later becomes
reoxygenated and attempts to divide. Finally, any diffusion
of AQ4, the reduction product, to an adjacent cell would
result in toxicity to that cell irrespective of its level of
oxygenation.
In previous studies we have derived a dose enhancement
ratio (DER) to assess bioreductive activation ofdrugs in vivo.
This was measured by assessing the enhancement of the
anti-tumour effect of the drug when the tumour was rendered
hypoxic in vivo using hypobaric hypoxia (McAleer et al.,
1992). When AQ4N was tested, it showed limited anti-
tumour effect at normal levels of oxygenation. With hypoxia
a significantly lower dose of AQ4N was required to give the
same anti-tumour effect with a DER of 5.1 (Figure 3), sug-
gesting that AQ4N may be toxic to hypoxic cells in vivo
through the production of AQ4. Although the DER for
AQ4N was less than that obtained previously with SR 4233
and RSU 1069 (Table I), AQ4N showed significant bioreduc-
tive potential as measured by this test system.
Ideally a bioreductive drug should show selective toxicity
to the treatment-resistant hypoxic cells of tumours, without
toxicity to normally oxygenated tissues. This should result in
sparing of normal tissues and yield a high therapeutic ratio.
In mice kept at normal levels of oxygenation AQ4N showed
only a minimal increase in systemic toxicity (as measured by
weight loss) with doses that showed measurable anti-tumour
effect. In particular, AQ4N showed almost no toxicity at
doses that gave effective enhancement of radiation induced
cell kill. In addition, systemic toxicity was not enhanced by
hypoxia at doses up to 50 mg kg-', although hypoxia did
potentiate systemic toxicity at higher doses of AQ4N. This
suggests that normal tissues in these mice could metabolise
the drug only when oxygen levels were artificially reduced.
The striking toxicity of SR 4233 in oxic mice at doses
approaching the maximum tolerated dose suggest that
sufficient metabolism of SR 4233 occurred systemically under
conditions of normal oxygenation. This effect was further
enhanced by hypoxia. Minchinton and Brown (1992)
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obtained milar results for SR 4233 when it was
administered in combination with normobaric hypoxia (10%
oxygen). In contrast, RSU 1069 showed significnt toxicity
only in hypoxc mice. The recent study by Koch (1993)
provides an explanation for the higher systemic toxicity of
SR 4233 shown both in our studies and that of Minchinton
and Brown (1992).
Clinical use of bioreductive drugs will require their com-
bination with an agent toxic to well-oxygenated cells. Inves-
tigation of AQ4N with radiation showed it to be a very
efficent dose-spanng agent, giving a substantal reduction
(50%) in radiation dose to give the same anti-tumour effect
(Figure 5). Several similar studies have shown additive or
supra-additive interactions when bioreductive drugs are com-
bined with radiation treatments (Brown and lemmon, 1991;
Cole et a., 1991; Grau and Overgaard, 1991). The maximal
effect reported in these studies was found when the interval
between administration of the two modaltimes was less than
24 h. With AQ4N a maximal effect can be eliiteod even if the
drug is admnistered 4 days before radiation. [Te current
experiments did not lend themselves to full isobologram
analysis since AQ4N alone does not give an 18 day growth
delay (unpubished data), thus preventing the derivation of
the complete additivity envelope].
Ifradiation is administered at approximately the same time
as a putative bioreductive drug, a positive interaction can be
anticpated snce the two modaLities are cytotoic to different
cell subpopulations, i.e. the oxic and hypoxic fractions. With
AQ4N the observed interaction is maintained even when the
drug is administered up to 4 days before radiation. As dis-
cusse, the major reduction product of AQ4N in vitro is the
highly DNA affinic agent AQ4. Our results suggest that
AQ4N (t12 = 30min in mice) is metabolised to a cytotoxic
agent, presumably AQ4, with a long half-life in vimo. Even if
the drug is administered 4 days before radiation almost no
effect is seen on tumour growth, yet the additional insult of
irradiation causes a much greater anti-tumour effect than
that found in controls. Administration of radiation to a
tumour results in oxic cell kill and reoxygenation of hypoxic
cells, which may divide to repopulate the tumour. If the
hypoxic cells contain bound AQ4 this will inhibit cell cycle
progression by reoxygenated cells since it is a topoisomerase
H inhibitor. Our results suggest that this can occur even 4
days after administration of the pro-drug. On a longer time
scale AQ4 containing hypoxic cells should die and be lost
from the tumour. New hypoxic cells would be generated and
the interaction with radiation lost. We were unable to dem-
onstrate this as the end point of tumour growth delay
restricts the interval between treatments which can be
assessed
When AQ4N was dmin up to 6 h after irradiation
the maximal growth delay of 18 days was elicited. Since the
nance anti-tumour effect occurs postirradiation, this pro-
vides eviden that AQ4N is not a radiosenstiser but is
acting as a bioreductive drug. There was a 6-48 h period
after irradiation when the enhanced anti-tumour effect was
still apparent although diminishing. If AQ4N was given
immediately after irradiation it may be metabolised to pro-
duce AQ4 in hypoxic cells and prevent them from
repopulating the tumour. If this time interval is prolonged
regeneration of the oxic fraction will occur from the residual,
mainly hypoxic, cells. Thus the number of cells sensitive to
AQ4N will be reduced. Moore (1988) used split dose data
and found that the oxic fraction was regenerated by about 3
days. This would explain why AQ4N retained its activity
when administered up to 48 h after irradiation as the tumour
would still have a large number of sensitive hypoxic cells.
Clinical radiotherapy is normally given as a fractionated
regimen. When AQ4N was administered with fractionated
radiation the extent of anti-tumour toxicity was similar to
that obtained with the single-dose experiments. The most
effective outcome was obtained when the AQ4N was also
split into five equal doses given daily with radiation. This
suggests that on each day of aministration a small addi-
tional fraction of acutely hypoxic cells was killed, increasng
the anti-tumour effect. The phenomenon of acute hypoxia
has been described previously by Trotter et al. (1990). A
significantly increased anti-tumour effect was obtained with a
single dose ofdrug combined with five fractions of radiation,
although this was not as effective as that found when both
modalities were administered as fractionated regimens. The
results suggest that AQ4N may have considerable potential
for combination with fractionated radiation schedules at drug
doses that should not cause systemic toxicity. Further studies
are planned to examine dosing schedules for both modalities.
In conclusion, AQ4N is a novel drug which shows
bioreductive activation nvivo. We have shown AQ4N to
have an additive anti-tumour effect when combined with
radiation, even when there is a long separation time between
administation of the two modalities. Our studies have high-
lighted four major properties of AQ4N which might be
exploited in clinical studies. (1) When given in combination
with radiation AQ4N allows a significant reduction in radia-
tion dose for an equivalent anti-tumour effect. (2) AQ4N has
minimal toxicity at doses effective in combined modality
expeLimes, suting that the radiation sparing may be
achieved without advese sstemi toxicity. (3) The dose-
sparing effect can be elicited even if AQ4N is administed
several hours (even days) before the radiation. This schedul-
ing should allow sufficient time for the prodrug to be
eliminated from normal tisues before irTadiation, thus reduc-
ing the risk of hand, drug-related, normal tissue toxicity
in the radiation fiel (4) An equally effective interaction is
obWained when AQ4N is combined with fractionated radia-
tion, suggesting potential for AQ4N to be combined with
clinical radiotherapy regimens.
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